Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vanda Pharmaceuticals Inc. (VNDA : NSDQ)

• Company Description    Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. Number of Employees: 533

• Price / Volume Information    Yesterday's Closing Price: $6.19 Daily Weekly Monthly 20 Day Moving Average: 1,203,668 shares Shares Outstanding: 60.13 (millions) Market Capitalization: $372.24 (millions) Beta: 0.65 52 Week High: $9.94 52 Week Low: $4.14 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.47% -11.99% 12 Week -28.02% -33.46% Year To Date -29.82% -35.27%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2200 PENNSYLVANIA AVENUE NW SUITE 300E - WASHINGTON,DC 20037 USA ph: 202-734-3400 fax: 202-296-1450 pr@vandapharma.com http://www.vandapharma.com

• General Corporate Information    Officers Mihael H. Polymeropoulos - Chief Executive Officer; President and Chairman Kevin Moran - Chief Financial Officer and Senior Vice President Richard W. Dugan - Director Anne Sempowski Ward - Director Phaedra Chrousos - Director Peer Information Vanda Pharmaceuticals Inc. (CORR.) Vanda Pharmaceuticals Inc. (RSPI) Vanda Pharmaceuticals Inc. (CGXP) Vanda Pharmaceuticals Inc. (BGEN) Vanda Pharmaceuticals Inc. (GTBP) Vanda Pharmaceuticals Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 921659108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 07/30/26 Share - Related Items Shares Outstanding: 60.13 Most Recent Split Date: (:1) Beta: 0.65 Market Capitalization: $372.24 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.50 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.27 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/30/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.33 Price/Cash Flow: - Price / Sales: 1.71 EPS Growth vs. Year Ago Period: -64.00% vs. Previous Quarter: -78.26% Sales Growth vs. Year Ago Period: 3.35% vs. Previous Quarter: -9.61% ROE 03/31/26 - -32.26 12/31/25 - -23.85 09/30/25 - -16.82 ROA 03/31/26 - -23.43 12/31/25 - -18.20 09/30/25 - -13.40 Current Ratio 03/31/26 - 2.16 12/31/25 - 2.39 09/30/25 - 3.12 Quick Ratio 03/31/26 - 2.15 12/31/25 - 2.38 09/30/25 - 3.10 Operating Margin 03/31/26 - -57.79 12/31/25 - -49.41 09/30/25 - -39.70 Net Margin 03/31/26 - -109.99 12/31/25 - -102.02 09/30/25 - -39.70 Pre-Tax Margin 03/31/26 - -68.74 12/31/25 - -64.16 09/30/25 - -50.52 Book Value 03/31/26 - 4.67 12/31/25 - 5.54 09/30/25 - 7.89 Inventory Turnover 03/31/26 - 6.54 12/31/25 - 6.53 09/30/25 - 6.01 Debt-to-Equity 03/31/26 - 0.01 12/31/25 - 0.01 09/30/25 - 0.01 Debt-to-Capital 03/31/26 - 1.33 12/31/25 - 1.23 09/30/25 - 0.60

Powered by Zacks Investment Research ©